Aromatization and the Estrogen Pathway in Men: What Happens to Your Testosterone

What Aromatization Actually Is

Aromatization is the enzymatic conversion of androgens (primarily testosterone and androstenedione) into estrogens (primarily estradiol and estrone) catalyzed by the enzyme aromatase, encoded by the gene CYP19A1. The reaction removes the C-19 methyl group from the androgen A-ring, produces the characteristic phenolic A-ring of estrogens, and releases formic acid as a byproduct. In men, this happens continuously in multiple tissues, not just the gonads.

The Leydig cells of the testes produce most circulating testosterone, but aromatization is largely a peripheral event. Adipose tissue carries the highest aromatase activity in men, which is why body-fat percentage directly predicts estradiol levels [1]. Liver, skin, bone, and neurons all express CYP19A1 at lower levels. Brain-specific aromatization matters for libido, mood regulation, and bone mineral density independent of systemic estradiol [2].

Men who lack functional aromatase due to CYP19A1 loss-of-function mutations develop severe osteoporosis, unfused epiphyses, and insulin resistance despite high testosterone levels, a finding that demonstrates how necessary estradiol is in male physiology [3]. Estrogen deprivation, not just excess, is clinically dangerous.

Aromatase activity rises with: increasing adipose mass, age-related changes in enzyme expression, alcohol intake, certain medications (notably valproate and some antifungals), and exogenous testosterone administration. It falls with: weight loss, zinc supplementation at pharmacological doses, and aromatase inhibitor (AI) drugs.

The HPG Axis and How Estradiol Feeds Back

The hypothalamic-pituitary-gonadal (HPG) axis is the hormonal cascade that governs testosterone production. The hypothalamus releases gonadotropin-releasing hormone (GnRH) in pulses. GnRH signals the anterior pituitary to secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH drives Leydig cell testosterone synthesis. Testosterone and estradiol both feed back to suppress further GnRH and LH release, completing the loop [4].

For decades the dominant model assumed testosterone alone drove negative feedback at the hypothalamus. A 2001 study by Finkelstein et al. and a more definitive 2013 NEJM study (N=198) challenged that assumption directly. Finkelstein et al. found that estradiol, not testosterone, was the primary regulator of fat mass, and that both hormones contributed to libido and sexual function, with estradiol playing the larger role in suppressing LH [5]. The 2013 paper assigned male body-composition changes more to estradiol deficiency than to testosterone deficiency alone.

This has direct clinical implications for TRT management. When a man begins exogenous testosterone, total testosterone rises, aromatase converts a portion to estradiol, and both hormones suppress LH and FSH. The testes stop receiving LH signals and reduce endogenous production. This is HPG axis suppression, and it is the mechanism behind testicular atrophy and impaired spermatogenesis seen on TRT without adjunct therapy [6]. Human chorionic gonadotropin (hCG) is used at doses of 500, 1 to 000 IU two to three times per week to mimic LH and preserve testicular function during TRT.

The degree of HPG suppression on TRT depends on the testosterone dose, the resulting estradiol level, SHBG concentration, and individual GnRH pulse sensitivity. There is no single threshold at which suppression becomes total, but intramuscular testosterone cypionate at 200 mg per week typically suppresses LH to below 1.0 mIU/mL within two to four weeks in most men.

Free Testosterone vs. Total Testosterone: Why the Distinction Matters

A standard testosterone blood draw reports total testosterone, the sum of every testosterone molecule in the sample whether bound to protein or not. That number alone does not tell you how much testosterone is available to enter cells and activate androgen receptors.

Testosterone circulates in three pools. Approximately 44 to 65% is tightly bound to sex hormone-binding globulin (SHBG). Another 30 to 40% is loosely bound to albumin. Only 2 to 3% is unbound, which is free testosterone [7]. The albumin-bound fraction releases testosterone readily at the tissue level because albumin's binding affinity is low (association constant approximately 3.6 x 10^4 L/mol). SHBG-bound testosterone does not dissociate readily and is generally considered biologically inactive. Bioavailable testosterone = free testosterone plus albumin-bound testosterone.

A man with a total testosterone of 500 ng/dL and high SHBG (say, 70 nmol/L) may have a free testosterone of only 6 to 7 ng/dL, which falls below the lower reference limit of approximately 9 to 10 ng/dL used in most labs [8]. That man may have textbook-low androgen symptoms despite a "normal" total testosterone. Conversely, a man with low SHBG (say, 15 nmol/L) and total testosterone of 380 ng/dL may have a free testosterone at the high end of normal.

The Endocrine Society 2018 guideline states: "We suggest using free testosterone measurement to evaluate men with symptoms of androgen deficiency who have total testosterone levels near the lower limit of the normal range, and in men who have conditions that can alter SHBG levels." [9] That quotation comes directly from the clinical practice guideline (Bhasin S et al., 2018).

Free testosterone can be measured directly by equilibrium dialysis (the gold standard, but expensive and not universally available) or estimated by calculation using total testosterone, SHBG, and albumin via the Vermeulen equation [10]. The calculated free testosterone using the Vermeulen formula correlates well with equilibrium dialysis in men who are not obese and do not have extreme SHBG values.

SHBG Explained: The Protein That Controls Your Androgen Access

Sex hormone-binding globulin is a glycoprotein produced primarily by the liver. It binds testosterone with roughly three times the affinity it binds estradiol, and with far greater affinity than it binds DHEA or androstenedione. Because SHBG sequesters testosterone so effectively, any change in SHBG concentration shifts the free testosterone level even when total testosterone stays constant [11].

SHBG rises with: aging (SHBG increases roughly 1 to 2% per year after age 40), liver disease (especially hepatitis and cirrhosis), hyperthyroidism, caloric restriction, estrogen administration, and certain anticonvulsants. SHBG falls with: obesity, hypothyroidism, insulin resistance, exogenous androgens, and glucocorticoid use [12].

Estradiol itself is a weak inducer of hepatic SHBG production. When aromatization runs high and estradiol rises, SHBG may rise modestly in response, further reducing free testosterone. This creates a negative feedback loop where high aromatization reduces bioavailable testosterone not only by consuming it but also by secondarily raising SHBG.

In clinical practice, SHBG measurement is essential for interpreting testosterone labs. A man presenting with low-T symptoms and a total testosterone of 350 ng/dL requires SHBG testing before a diagnosis is confirmed or TRT is initiated. Without SHBG, you cannot calculate bioavailable testosterone, and you may either over-treat a man with low SHBG or under-treat one with high SHBG.

Reference ranges for SHBG in adult men are typically 10, 57 nmol/L, but optimal levels for men on TRT are debated. Many TRT-experienced clinicians target SHBG between 20, 40 nmol/L for the best ratio of free to total testosterone.

How TRT Alters the Aromatization-Estradiol Balance

Exogenous testosterone doses used in TRT (typically 50 to 200 mg/week of testosterone cypionate or enanthate, or 40 to 80 mg/day of testosterone cream) raise circulating testosterone significantly above endogenous production rates. Aromatase activity does not scale linearly with substrate; it saturates at high substrate concentrations. Still, at the supraphysiologic peaks that occur with weekly injections, enough conversion occurs to raise estradiol well above baseline.

A 2001 dose-finding study by Bhasin et al. in NEJM (N=61 healthy men given testosterone enanthate at 25, 50, 125, 300, or 600 mg/week) showed that estradiol levels rose in a dose-dependent manner, reaching concentrations associated with suppressed LH at the 300 and 600 mg doses [13]. Even at the 125 mg/week dose, estradiol was measurably elevated versus placebo. In TRT-range doses (100 to 200 mg/week), estradiol commonly rises to 40, 80 pg/mL in men without AI use, above the commonly cited upper reference limit of 40, 42 pg/mL.

Elevated estradiol in men on TRT may cause gynecomastia, water retention, mood changes, and reduced libido at very high levels. Estradiol that is too low (from over-aggressive AI use or under-dosing) may cause joint pain, low bone density, poor sleep, reduced libido, and cardiovascular risk [14].

The Endocrine Society guideline does not recommend routine AI use during TRT. The 2018 guideline explicitly states: "We recommend against using aromatase inhibitors routinely in men with hypogonadism." [9] AI use is reserved for symptomatic estradiol elevation confirmed on labs, specifically in men with estradiol above 40, 50 pg/mL who have attributable symptoms.

When an AI is used, anastrozole 0.25 to 0.5 mg twice weekly is the most common starting point in TRT practice. Exemestane 12.5 mg twice weekly is a steroidal alternative that carries a lower risk of driving estradiol to undetectable levels. Dose titration should target estradiol in the 20, 35 pg/mL range while monitoring bone markers in long-term users.

Adipose Tissue as the Master Aromatase Organ

Body fat is not inert storage. Adipose stromal cells express CYP19A1 at concentrations high enough to make fat mass the dominant site of estradiol production in men. A study in The Journal of Clinical Endocrinology and Metabolism found that aromatase activity in adipose tissue correlates directly with fat mass index, and that weight loss of 10% body weight reduced estradiol by a mean of 17% in obese men [15].

This explains several clinical observations. Obese men have disproportionately high estradiol, disproportionately low free testosterone (from both SHBG effects and elevated conversion), and stronger HPG axis suppression than lean men at the same testosterone dose. Men starting TRT while obese often require more careful estradiol monitoring and may see estradiol normalize after significant fat loss without any AI use.

Visceral adipose tissue appears to carry higher aromatase activity per gram than subcutaneous fat, which is why waist circumference may be a better predictor of estradiol elevation than total body weight [16]. Lifestyle interventions that specifically reduce visceral fat, including caloric deficit, resistance training, and GLP-1 receptor agonist therapy in eligible patients, can meaningfully shift the testosterone-to-estradiol ratio.

Bioavailable Testosterone: The Number That Most TRT Panels Miss

Most direct-to-consumer testosterone test kits and many primary care panels report only total testosterone. Bioavailable testosterone (free plus albumin-bound) provides a more clinically relevant estimate of androgen activity at the tissue level, but measuring it requires either equilibrium dialysis with protein precipitation (ammonium sulfate precipitation assay) or calculation from total testosterone, SHBG, and albumin.

The normal reference range for bioavailable testosterone in adult men aged 20, 40 is approximately 130 to 280 ng/dL in most laboratory databases, though the exact range varies with the assay method [17]. Levels below 70 to 80 ng/dL are associated with symptomatic hypogonadism regardless of total testosterone.

The practical clinical sequence for full androgen assessment is: (1) draw total testosterone, SHBG, and albumin in the morning (before 10 a.m.) on two separate occasions, (2) calculate free testosterone via the Vermeulen formula or request equilibrium dialysis, (3) calculate bioavailable testosterone, (4) measure estradiol by sensitive LC-MS/MS assay (not immunoassay, which overestimates in men) [18]. LC-MS/MS estradiol assays in men should target a reference range of 10, 40 pg/mL.

Getting this sequence right before initiating TRT avoids misdiagnosis and avoids giving testosterone to men whose symptoms arise from elevated SHBG, undiagnosed hypothyroidism, or elevated estradiol from obesity rather than from primary hypogonadal testosterone deficiency.

Managing Estrogen on TRT: A Practical Clinical Framework

Estradiol management on TRT is not about suppressing estrogen to zero. It is about keeping estradiol in a range that allows its beneficial effects (bone density, libido, cardiovascular protection, mood stability) while preventing the side effects of excess (gynecomastia, water retention, blunted libido at very high levels).

Step 1: Establish the baseline. Before TRT, measure total testosterone, free testosterone (calculated or dialysis), SHBG, albumin, and estradiol by LC-MS/MS. Measure LH and FSH to characterize HPG axis status.

Step 2: Choose a delivery route that smooths peaks. Daily testosterone cream (40 to 80 mg/day) produces smaller estradiol excursions than weekly injections because peak testosterone concentration is lower. Twice-weekly injection of the total weekly dose also reduces peaks versus once-weekly dosing.

Step 3: Monitor at 6 to 8 weeks. Recheck the full panel. If estradiol exceeds 40, 50 pg/mL and the patient has attributable symptoms, consider anastrozole 0.25 mg twice weekly before escalating the testosterone dose.

Step 4: Recheck at 12 weeks. Target estradiol 20, 35 pg/mL, free testosterone at or above the lower quartile of the reference range for age 20, 40, and SHBG stable. Adjust AI dose in 0.25 mg increments.

Step 5: Annual bone density. Men on long-term AI therapy should have DEXA scans. Estradiol below 15, 20 pg/mL is associated with accelerated bone loss in men, as demonstrated in the CYP19A1 mutation case series [3].

Testosterone dose, injection frequency, body composition, and individual CYP19A1 expression variation all affect where any given man's estradiol settles. Lab-guided titration, not fixed-dose protocols, is the standard of care per Endocrine Society guidance [9].